ETF Daily News3d
Zymeworks (ZYME) Expected to Announce Earnings on Wednesday
In other Zymeworks news, Director Ecor1 Capital, Llc bought 11,958 shares of the firm’s stock in a transaction dated Tuesday, December 24th. The stock was acquired at an average cost of $14.12 ...
The National Law Review2d
Zymeworks Announces Achievement of $14 Million Milestone from GSK Collaboration
Zymeworks believes there is a reasonable basis for its expectations and beliefs, but they are inherently uncertain. Zymeworks may not realize its expectations, and its beliefs may not prove ...
Yahoo Finance10d
Zymeworks Announces Appointment of Oleg Nodelman to Board of Directors
VANCOUVER, British Columbia, Feb. 18, 2025 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage ...
Nasdaq3d
Zymeworks Inc. Announces Participation in Upcoming Investor Conferences in March 2025
Zymeworks Inc., a clinical-stage biotechnology company focused on developing innovative biotherapeutics for challenging diseases such as cancer, inflammation, and autoimmune disorders, has ...
Zymeworks Inc. (NYSE:ZYME) Receives Consensus Recommendation of “Moderate Buy” from Brokerages
Zymeworks Inc. (NYSE:ZYME – Get Free Report) has been given a consensus rating of “Moderate Buy” by the seven research firms ...
Yahoo Finance3d
Zymeworks Announces Participation in Upcoming Investor Conferences
Zymeworks Inc. VANCOUVER, British Columbia, Feb. 25, 2025 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company developing a diverse pipeline of novel ...
Nasdaq29d
Zymeworks Inc. Management to Participate in Upcoming Investor Conferences in February 2025
Zymeworks Inc., a clinical-stage biotechnology company based in Vancouver, is focused on developing novel biotherapeutics for challenging diseases such as cancer and autoimmune conditions.